320 related articles for article (PubMed ID: 24239904)
1. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
Höppner S; Delahaut P; Schänzer W; Thevis M
J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes.
Höppner S; Schänzer W; Thevis M
J Mass Spectrom; 2013 Jul; 48(7):830-43. PubMed ID: 23832939
[TBL] [Abstract][Full Text] [Related]
3. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
Höppner S; Schänzer W; Thevis M
Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
5. Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing.
Tretzel L; Thomas A; Piper T; Hedeland M; Geyer H; Schänzer W; Thevis M
J Pharm Biomed Anal; 2016 May; 123():132-40. PubMed ID: 26896632
[TBL] [Abstract][Full Text] [Related]
6. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
[TBL] [Abstract][Full Text] [Related]
8. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.
Guddat S; Solymos E; Orlovius A; Thomas A; Sigmund G; Geyer H; Thevis M; Schänzer W
Drug Test Anal; 2011; 3(11-12):836-50. PubMed ID: 22135086
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometric detection of peginesatide in human urine in doping control analysis.
Möller I; Thomas A; Delahaut P; Geyer H; Schänzer W; Thevis M
J Pharm Biomed Anal; 2012 Nov; 70():512-7. PubMed ID: 22884786
[TBL] [Abstract][Full Text] [Related]
11. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
Thevis M; Krug O; Schänzer W
Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
[TBL] [Abstract][Full Text] [Related]
13. A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes.
Mazzarino M; Cesarei L; de la Torre X; Fiacco I; Robach P; Botrè F
J Pharm Biomed Anal; 2016 Jan; 117():47-60. PubMed ID: 26342446
[TBL] [Abstract][Full Text] [Related]
14. High-throughput and sensitive screening by ultra-performance liquid chromatography tandem mass spectrometry of diuretics and other doping agents.
Ventura R; Roig M; Montfort N; Sáez P; Bergés R; Segura J
Eur J Mass Spectrom (Chichester); 2008; 14(3):191-200. PubMed ID: 18708699
[TBL] [Abstract][Full Text] [Related]
15. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
[TBL] [Abstract][Full Text] [Related]
16. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.
Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M
Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894
[TBL] [Abstract][Full Text] [Related]
17. Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing.
Dib J; Schlörer N; Schänzer W; Thevis M
J Mass Spectrom; 2015 Feb; 50(2):407-17. PubMed ID: 25800023
[TBL] [Abstract][Full Text] [Related]
18. Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?
Thevis M; Kuuranne T; Dib J; Thomas A; Geyer H
Drug Test Anal; 2020 Jun; 12(6):704-710. PubMed ID: 32180361
[TBL] [Abstract][Full Text] [Related]
19. Quantification of insulin-like growth factor-1 in dried blood spots for detection of growth hormone abuse in sport.
Cox HD; Rampton J; Eichner D
Anal Bioanal Chem; 2013 Feb; 405(6):1949-58. PubMed ID: 23263515
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-high resolution/ high accuracy (tandem) mass spectrometry-based identification of in vivo generated metabolites of the selective androgen receptor modulator ACP-105 for doping control purposes.
Thevis M; Thomas A; Piper T; Krug O; Delahaut P; Schänzer W
Eur J Mass Spectrom (Chichester); 2014; 20(1):73-83. PubMed ID: 24881457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
